Improve attention during brain stimulation

Trial ID
NCT06899022
Official Title
Investigating the Role of Attention in Perceptual and Cognitive Consequences of Parkinson's Disease
Goal
Improve attention during brain stimulation
Phase
NA
Status
RECRUITING
Sponsor
University of Nebraska
Study Type
INTERVENTIONAL
Enrollment
138 participants
Conditions
Essential Tremor, Parkinson's Disease (PD)
Interventions
Normal therapeutic DBS, Reduced current DBS, Reduced frequency DBS

Plain-Language Summary

The goal is to understand how attention changes contribute to the perceptual and cognitive problems people with Parkinson's or essential tremor sometimes experience, especially in relation to deep brain stimulation. The team will compare normal therapeutic DBS with reduced current and reduced frequency settings, since DBS delivers electrical pulses to targets like the STN, GPi, or VIM to reduce motor symptoms, and changing the strength or timing of that stimulation can alter attention, perception, and how DBS interacts with medications such as levodopa. Some participants will do perceptual tasks during awake DBS implantation with microelectrode recordings, and others will have brief, controlled adjustments to their implanted DBS while reporting judgments with a button or slider. Eligible people are age 19 to 90 with Parkinson's or essential tremor who are scheduled for new therapeutic DBS, can follow task instructions and use a button or mouse, and can tolerate short changes in stimulation; age-matched healthy controls are also recruited, while people with poor visual acuity or who cannot complete tasks are excluded.

Locations

  • University of Nebraska Medical Center, Omaha, Nebraska, United States

Frequently Asked Questions

What is this trial testing?
This trial is studying Normal therapeutic DBS. The goal is to understand how attention changes contribute to the perceptual and cognitive problems people with Parkinson's or essential tremor sometimes experience, especially in relation to deep brain stimulation. The team will compare normal therapeutic DBS with reduced current and reduced frequency settings, since DBS delivers electrical pulses to targets like the STN, GPi, or VIM to reduce motor symptoms, and changing the strength or timing of that stimulation can alter attention, perception, and how DBS interacts with medications such as levodopa. Some participants will do perceptual tasks during awake DBS implantation with microelectrode recordings, and others will have brief, controlled adjustments to their implanted DBS while reporting judgments with a button or slider. Eligible people are age 19 to 90 with Parkinson's or essential tremor who are scheduled for new therapeutic DBS, can follow task instructions and use a button or mouse, and can tolerate short changes in stimulation; age-matched healthy controls are also recruited, while people with poor visual acuity or who cannot complete tasks are excluded.
Who can participate?
Participants must be between 19 Years and 90 Years.
Where is this trial located?
This trial is recruiting at 1 location.
Does it cost anything to join?
No. There is no cost to participate. Study-related care and treatment are provided at no charge.
How long does the trial last?
This trial is estimated to last approximately 2 years and 4 months.

View on ClinicalTrials.gov